Potential multisystem degeneration in Asidan patients

Yasuyuki Ohta, Toru Yamashita, Nozomi Hishikawa, Kota Sato, Kosuke Matsuzono, Keiichiro Tsunoda, Noriko Hatanaka, Mami Takemoto, Toshihiko Takemi, Kazuhiro Takamatsu, Koji Abe

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective To evaluate a potential multisystem involvement of neurodegeneration in Asidan, in addition to cerebellar ataxia and signs of motor neuron disease. Methods We compared the new Asidan patients and those identified in previous studies with Parkinson's disease (PD, n = 21), and progressive supranuclear palsy (PSP, n = 13) patients using 123I-2β-Carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT) dopamine transporter single photon emission computed tomography (DAT-SPECT) and 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy (Asidan, DAT: n = 10; MIBG: n = 15). Results Both the PD and PSP groups served as positive controls for DAT decline. The PD and PSP groups served as a positive and negative control, respectively, of MIBG decline in the early phase H/M ratio. Of the Asidan patients, 60.0% showed DAT decline without evident parkinsonian features and 6.7% showed impaired MIBG in only the delayed phase H/M ratio. Combined with a normal range of the early phase H/M ratio, this phenotype was newly named Declined DAT Without Evident Parkinsonism (DWEP). Interpretation The results of present study including DWEP suggest a wider spectrum of neurodegeneration for extrapyramidal and autonomic systems in Asidan patients than expected, involving cerebellar, motor system and cognitive functioning.

Original languageEnglish
Pages (from-to)216-222
Number of pages7
JournalJournal of the Neurological Sciences
Volume373
DOIs
Publication statusPublished - Feb 15 2017

Fingerprint

Cell Division
Parkinsonian Disorders
Nortropanes
Progressive Supranuclear Palsy
Cerebellar Ataxia
Motor Neuron Disease
Dopamine Plasma Membrane Transport Proteins
Myocardial Perfusion Imaging
Single-Photon Emission-Computed Tomography
Parkinson Disease
Reference Values
Phenotype
Primary Spontaneous Pneumothorax
2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane

Keywords

  • Asidan
  • DAT
  • MIBG
  • PD
  • PSP
  • SCA36

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Potential multisystem degeneration in Asidan patients. / Ohta, Yasuyuki; Yamashita, Toru; Hishikawa, Nozomi; Sato, Kota; Matsuzono, Kosuke; Tsunoda, Keiichiro; Hatanaka, Noriko; Takemoto, Mami; Takemi, Toshihiko; Takamatsu, Kazuhiro; Abe, Koji.

In: Journal of the Neurological Sciences, Vol. 373, 15.02.2017, p. 216-222.

Research output: Contribution to journalArticle

Ohta, Yasuyuki ; Yamashita, Toru ; Hishikawa, Nozomi ; Sato, Kota ; Matsuzono, Kosuke ; Tsunoda, Keiichiro ; Hatanaka, Noriko ; Takemoto, Mami ; Takemi, Toshihiko ; Takamatsu, Kazuhiro ; Abe, Koji. / Potential multisystem degeneration in Asidan patients. In: Journal of the Neurological Sciences. 2017 ; Vol. 373. pp. 216-222.
@article{0df3b19983cf4d2b931e06aef56650b4,
title = "Potential multisystem degeneration in Asidan patients",
abstract = "Objective To evaluate a potential multisystem involvement of neurodegeneration in Asidan, in addition to cerebellar ataxia and signs of motor neuron disease. Methods We compared the new Asidan patients and those identified in previous studies with Parkinson's disease (PD, n = 21), and progressive supranuclear palsy (PSP, n = 13) patients using 123I-2β-Carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT) dopamine transporter single photon emission computed tomography (DAT-SPECT) and 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy (Asidan, DAT: n = 10; MIBG: n = 15). Results Both the PD and PSP groups served as positive controls for DAT decline. The PD and PSP groups served as a positive and negative control, respectively, of MIBG decline in the early phase H/M ratio. Of the Asidan patients, 60.0{\%} showed DAT decline without evident parkinsonian features and 6.7{\%} showed impaired MIBG in only the delayed phase H/M ratio. Combined with a normal range of the early phase H/M ratio, this phenotype was newly named Declined DAT Without Evident Parkinsonism (DWEP). Interpretation The results of present study including DWEP suggest a wider spectrum of neurodegeneration for extrapyramidal and autonomic systems in Asidan patients than expected, involving cerebellar, motor system and cognitive functioning.",
keywords = "Asidan, DAT, MIBG, PD, PSP, SCA36",
author = "Yasuyuki Ohta and Toru Yamashita and Nozomi Hishikawa and Kota Sato and Kosuke Matsuzono and Keiichiro Tsunoda and Noriko Hatanaka and Mami Takemoto and Toshihiko Takemi and Kazuhiro Takamatsu and Koji Abe",
year = "2017",
month = "2",
day = "15",
doi = "10.1016/j.jns.2017.01.003",
language = "English",
volume = "373",
pages = "216--222",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Potential multisystem degeneration in Asidan patients

AU - Ohta, Yasuyuki

AU - Yamashita, Toru

AU - Hishikawa, Nozomi

AU - Sato, Kota

AU - Matsuzono, Kosuke

AU - Tsunoda, Keiichiro

AU - Hatanaka, Noriko

AU - Takemoto, Mami

AU - Takemi, Toshihiko

AU - Takamatsu, Kazuhiro

AU - Abe, Koji

PY - 2017/2/15

Y1 - 2017/2/15

N2 - Objective To evaluate a potential multisystem involvement of neurodegeneration in Asidan, in addition to cerebellar ataxia and signs of motor neuron disease. Methods We compared the new Asidan patients and those identified in previous studies with Parkinson's disease (PD, n = 21), and progressive supranuclear palsy (PSP, n = 13) patients using 123I-2β-Carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT) dopamine transporter single photon emission computed tomography (DAT-SPECT) and 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy (Asidan, DAT: n = 10; MIBG: n = 15). Results Both the PD and PSP groups served as positive controls for DAT decline. The PD and PSP groups served as a positive and negative control, respectively, of MIBG decline in the early phase H/M ratio. Of the Asidan patients, 60.0% showed DAT decline without evident parkinsonian features and 6.7% showed impaired MIBG in only the delayed phase H/M ratio. Combined with a normal range of the early phase H/M ratio, this phenotype was newly named Declined DAT Without Evident Parkinsonism (DWEP). Interpretation The results of present study including DWEP suggest a wider spectrum of neurodegeneration for extrapyramidal and autonomic systems in Asidan patients than expected, involving cerebellar, motor system and cognitive functioning.

AB - Objective To evaluate a potential multisystem involvement of neurodegeneration in Asidan, in addition to cerebellar ataxia and signs of motor neuron disease. Methods We compared the new Asidan patients and those identified in previous studies with Parkinson's disease (PD, n = 21), and progressive supranuclear palsy (PSP, n = 13) patients using 123I-2β-Carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT) dopamine transporter single photon emission computed tomography (DAT-SPECT) and 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy (Asidan, DAT: n = 10; MIBG: n = 15). Results Both the PD and PSP groups served as positive controls for DAT decline. The PD and PSP groups served as a positive and negative control, respectively, of MIBG decline in the early phase H/M ratio. Of the Asidan patients, 60.0% showed DAT decline without evident parkinsonian features and 6.7% showed impaired MIBG in only the delayed phase H/M ratio. Combined with a normal range of the early phase H/M ratio, this phenotype was newly named Declined DAT Without Evident Parkinsonism (DWEP). Interpretation The results of present study including DWEP suggest a wider spectrum of neurodegeneration for extrapyramidal and autonomic systems in Asidan patients than expected, involving cerebellar, motor system and cognitive functioning.

KW - Asidan

KW - DAT

KW - MIBG

KW - PD

KW - PSP

KW - SCA36

UR - http://www.scopus.com/inward/record.url?scp=85008324810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008324810&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2017.01.003

DO - 10.1016/j.jns.2017.01.003

M3 - Article

C2 - 28131191

AN - SCOPUS:85008324810

VL - 373

SP - 216

EP - 222

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

ER -